000298945 001__ 298945
000298945 005__ 20250827125447.0
000298945 0247_ $$2doi$$a10.1016/j.molmed.2025.01.008
000298945 0247_ $$2pmid$$apmid:39955217
000298945 0247_ $$2ISSN$$a1471-4914
000298945 0247_ $$2ISSN$$a1471-499X
000298945 0247_ $$2altmetric$$aaltmetric:174376024
000298945 037__ $$aDKFZ-2025-00379
000298945 041__ $$aEnglish
000298945 082__ $$a610
000298945 1001_ $$0P:(DE-He78)9a1cac3459b4368615b3d544b5682435$$aDe Santis, Alessandro$$b0$$eFirst author
000298945 245__ $$aMolecular subtypes of intrahepatic cholangiocarcinoma.
000298945 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000298945 3367_ $$2DRIVER$$aarticle
000298945 3367_ $$2DataCite$$aOutput Types/Journal article
000298945 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756292055_16148$$xReview Article
000298945 3367_ $$2BibTeX$$aARTICLE
000298945 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298945 3367_ $$00$$2EndNote$$aJournal Article
000298945 500__ $$a#EA:A430#LA:A430# / 2025 Aug;31(8):755-769
000298945 520__ $$aIntrahepatic cholangiocarcinoma (iCCA) presents in two clinically distinct subtypes: large duct (LD-iCCA) and small duct (SD-iCCA). These subtypes exhibit significant molecular, genetic, and histopathological differences that impact patient prognosis and treatment responsiveness. This review advocates for a subtype-specific approach to iCCA research and clinical management, including tailored therapeutic strategies that consider distinct genetic profiles and tumor microenvironments. Current therapeutic approaches hold promise, yet efficacy varies by subtype. Additionally, subtype-specific molecular diagnostics, including DNA methylation-based classifiers and transcriptomic sequencing, have shown potential in refining iCCA subclassification, thereby guiding precision medicine efforts. This article outlines existing clinical trials, key research trajectories, and future directions for developing more effective subtype-adapted therapies for iCCA.
000298945 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000298945 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298945 650_7 $$2Other$$aclinical trial
000298945 650_7 $$2Other$$aintrahepatic cholangiocarcinoma
000298945 650_7 $$2Other$$amolecular targeted therapy
000298945 650_7 $$2Other$$amutation
000298945 650_7 $$2Other$$asurvival
000298945 650_7 $$2Other$$atranslational research
000298945 7001_ $$0P:(DE-He78)0116f5652cc0dbf455e3aa3914740230$$aZhu, Lei$$b1$$eFirst author$$udkfz
000298945 7001_ $$0P:(DE-He78)27fb0d2bd2832c8c977e636025736942$$aTao, Jianxin$$b2$$udkfz
000298945 7001_ $$aReißfelder, Christoph$$b3
000298945 7001_ $$0P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e$$aSchölch, Sebastian$$b4$$eLast author$$udkfz
000298945 773__ $$0PERI:(DE-600)2155736-6$$a10.1016/j.molmed.2025.01.008$$gp. S1471491425000085$$n8$$p755-769$$tTrends in molecular medicine$$v31$$x1471-4914$$y2025
000298945 909CO $$ooai:inrepo02.dkfz.de:298945$$pVDB
000298945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9a1cac3459b4368615b3d544b5682435$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000298945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0116f5652cc0dbf455e3aa3914740230$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000298945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)27fb0d2bd2832c8c977e636025736942$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000298945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000298945 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000298945 9141_ $$y2025
000298945 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRENDS MOL MED : 2022$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000298945 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bTRENDS MOL MED : 2022$$d2025-01-06
000298945 9202_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x0
000298945 9201_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x0
000298945 9200_ $$0I:(DE-He78)A430-20160331$$kA430$$lNWG-KKE Translationale Chirurgische Onkologie$$x0
000298945 980__ $$ajournal
000298945 980__ $$aVDB
000298945 980__ $$aI:(DE-He78)A430-20160331
000298945 980__ $$aUNRESTRICTED